Examining the immunoreactivities of the receptor-binding domain of SARS-CoV-2 spike proteins using a panel of human monoclonal antibodies
Previously, a panel of human monoclonal antibodies (hMAbs) (PD5, SC23, and PD4) were isolated from convalescent patients to evaluate their therapeutic potential in the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the binding domains of these antibodies have not been...
محفوظ في:
المؤلف الرئيسي: | Tan, Jie Ling |
---|---|
مؤلفون آخرون: | Richard J Sugrue |
التنسيق: | Final Year Project |
اللغة: | English |
منشور في: |
Nanyang Technological University
2022
|
الموضوعات: | |
الوصول للمادة أونلاين: | https://hdl.handle.net/10356/157131 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Development of human monoclonal antibodies against SARS-CoV-2
بواسطة: Wong, Joel Xu En
منشور في: (2021) -
Interaction of SARS-CoV spike protein with lipid rafts of host cells during viral entry
بواسطة: Lu, Yanning
منشور في: (2008) -
Development of SARS-COV therapeutics using quaternary protein mimetics
بواسطة: Neo, Tuan Ling
منشور في: (2010) -
Study of sars-cov entry mechanism and development of protein mimetic inhibitors
بواسطة: Ji, Zhe
منشور في: (2011) -
Characterization of monoclonal antibody specificities against conformational epitopes of dengue NS1 glycoprotein.
بواسطة: Cheng, Wei.
منشور في: (2009)